Top MPN specialist, Dr. Srdan "Serge" Verstovsek with MD Anderson, discusses the latest in polycythemia vera or PV treatments, especially those emerging from ongoing research in clinical trials. Dr. Verstovsek talks about updates on a Phase 2 study on rusfertide, the way it's administered, how often, and talks also about ropeginterferon.

Full interview → Updated soon

The interview has only been edited for clarity.

Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
____________________________
Contents Of This Video:

00:00 Intro
00:30 Update on Phase 2 study on rusfertide
04:12 Rusefertide Shot Frequency
04:31 Rusfertide side effects
05:27 Latest Update on Ropeg for PV
09:52 Differences between hydroxyurea and ropeg
10:53 Ropeg: Side effects and quality of life issues

____________________________

#ThePatientStory #Myelofibrosis #bloodcancer #blooddisease #hematology #oncology #MPN #myeloproliferativeneoplasms #essentialthrombocythemia #polycythemiavera #clinicaltrials #relapsedrefractory #Patientcare #cancertreatment #Cartcelltherapy